MicroRNA-224 Suppresses Colorectal Cancer Cell Migration by Targeting Cdc42
Table 2
Clinical and genetic status and miR-224 expression level frequency in 79 colorectal cancer (CRC) patients.
Variable
MiR-224-lowa
MiR-224-highb
Odds ratio (95% CI)
value
Age
≤68 (median age)
19 (47.5%)
21 (53.8%)
1.29 (0.533~3.121)
0.573
>68 (median age)
21 (52.5%)
18 (46.2%)
Gender
Female
21 (52.5%)
14 (35.9%)
0.507 (0.206~1.248)
0.140
Male
19 (47.5%)
25 (64.1%)
Clinical stage
Stage I/II
23 (57.5%)
20 (51.3%)
1.285 (0.529~3.121)
0.579
Stage III/IV
17 (42.5%)
19 (48.7%)
Tumor T status
≤2
5 (12.5%)
6 (15.4%)
0.786 (0.219~2.822)
0.712
>2
35 (87.5%)
33 (84.6%)
Lymph node metastasis
No
24 (60%)
20 (51.3%)
1.425 (0.584~3.475)
0.436
Yes
16 (40%)
19 (48.7%)
Distant metastasis
No
36 (90%)
37 (94.9%)
0.487 (0.084~2.823)
0.422
Yes
4 (10%)
2 (5.1%)
APC
Normal
33 (82.5%)
22 (56.4%)
3.643 (1.297~10.228)
0.015
Mutated
7 (17.5%)
17 (43.6%)
TP53
Normal
11 (27.5%)
11 (28.2%)
0.966 (0.361~2.583)
0.945
Mutated
29 (72.5%)
28 (71.8%)
Samples expressed miR-224 at lower than the average −ΔCt value.
bSamples expressed miR-224 at higher than the average −ΔCt value. CI: confidence interval.
